Interleukin-6 Receptor Inhibition for Symptomatic Intracranial Atherosclerosis

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 486 participants.

Also called NCT06447701

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 486 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06447701
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT06447701. Randomized; quadruple masking; primary purpose treatment. Start 2025-10-30 (anticipated); primary completion 2025-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Interleukin-6 Receptor Inhibition for Symptomatic Intracranial Atherosclerosis
Acronym
IRIS-sICAS
Condition
Brain Diseases
Condition
Ischemia
Condition
Stroke
Condition
Cerebral Infarction
Condition
Atherosclerosis of Artery
Condition
Atheroscleroses, Intracranial
Intervention (Drug)
Tocilizumab
Intervention (Drug)
NaCl 0.9% 100ml
Lead sponsor
Zhujiang Hospital (class: other)
Collaborator
Shenzhen Second People's Hospital (class: other)
Collaborator
Central People's Hospital of Zhanjiang (class: other)
Collaborator
Shantou Central Hospital (class: other)
Collaborator
Eighth Affiliated Hospital, Sun Yat-sen University (class: other)
Collaborator
Guangzhou First People's Hospital (class: other)
Collaborator
Peking University Shenzhen Hospital (class: other)
Collaborator
Guangdong Provincial People's Hospital (class: other)

Record details

Record id
cardio:ct-nct06447701
Content hash
acb801452a9866f666e24c9a90ba1caeaeab15e99925d55e1d6c63297c19fe7e